How Effective Is Tremfya for Plaque Psoriasis?
Tremfya (guselkumab), an IL-23 inhibitor, treats moderate-to-severe plaque psoriasis in adults. In phase 3 trials like VOYAGE 1 and 2, 73-85% of patients achieved PASI 75 (75% skin clearance) at week 16, compared to 7-10% on placebo. By week 28, 80-91% reached PASI 90 (90% clearance), and 54-76% hit PASI 100 (complete clearance). These results held through week 100 with sustained dosing every 8 weeks.[1][2]
Real-world data from registries like Psoriasis Longitudinal Assessment and Registry (PSOLAR) show similar outcomes, with about 70% achieving PASI 90 at 6 months.[3]
How Does Tremfya Compare to Other Biologics?
Tremfya outperforms older TNF inhibitors like Humira (adalimumab), where PASI 75 rates were 67-80% at week 12 in head-to-head trials.[1] Against IL-17 inhibitors like Cosentyx (secukinumab), it matched or exceeded PASI 90 rates (70-80% at week 16) in ECLIPSE and GUIDE trials.[2][4] It shows faster onset than Stelara (ustekinumab), an IL-12/23 inhibitor, with superior PASI 90 at week 16 (84% vs. 62%).[1]
| Drug | PASI 75 at Week 16 | PASI 90 at Week 16 | PASI 100 at Week 16 |
|------|---------------------|---------------------|----------------------|
| Tremfya | 73-85% | 58-80% | 31-44% |
| Humira | 57-67% | 32-42% | 11-17% |
| Cosentyx | 80-84% | 59-70% | 31-38% |
| Stelara | 67-73% | 23-41% | 8-12% |
Data from pivotal trials; individual results vary.[1][2][4]
Who Responds Best and How Long Do Results Last?
Patients with higher baseline PASI scores (>20) see strong responses, with 80%+ PASI 90 by week 28. Scalp and nail psoriasis improve notably, with 70-80% clear or almost clear by week 16.[2] Efficacy lasts 2-5 years in long-term extensions, with low loss of response (under 10% annually).[3] Subcutaneous injections every 8 weeks maintain clearance.
What Do Clinical Guidelines Say?
The American Academy of Dermatology (AAD) and National Psoriasis Foundation rank IL-23 inhibitors like Tremfya as first-line for moderate-to-severe plaque psoriasis due to high efficacy, favorable safety, and dosing convenience. European guidelines (EDF) agree, preferring them over TNFs for biologic-naive patients.[5]
Common Patient-Reported Outcomes and Side Effects Impacting Effectiveness
Patients report quality-of-life gains, with Dermatology Life Quality Index (DLQI) scores dropping from 13-15 (severe impairment) to 1-3 (minimal) by week 16 in 70-80%.[2] Infections occur in 14-20% (mostly mild), but serious events are rare (1-2%), not undermining efficacy.[1] Weight gain (1-3 kg average) affects some but doesn't reduce skin response rates.
When Does Tremfya Fail or Lose Effectiveness?
Primary non-response hits 10-15%; switch to IL-17s yields 60-70% response.[3] Anti-drug antibodies develop in 7-10%, rarely neutralizing efficacy.[1] No major patent issues limit access; Janssen holds exclusivity until 2032-2033 in key markets.[6]
Sources
[1]: Tremfya Prescribing Information (Janssen)
[2]: NEJM: VOYAGE 1/2 Trials (2017)
[3]: J Am Acad Dermatol: Real-World Data (2022)
[4]: Lancet: ECLIPSE Trial (2019)
[5]: AAD Guidelines (2021)
[6]: DrugPatentWatch: Guselkumab Patents